Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd’s Q4 earnings beat, growth‑oriented pipeline, and disciplined outlook hint at upside potential for investors, despite modest FY‑26 guidance.

Teva Pharmaceutical’s stock surge, legal challenges, and investor gains revealed – explore how lawsuits over Victoza and Harel’s stake impact its future.

Teva secures EU approvals for two denosumab biosimilars, PONLIMSI and DEGEVMA, expanding its bone‑health portfolio and boosting market share prospects.